Latest Pharma and Biotech News
Pharmaceutical
22 January 2025 Johnson & Johnson presented its financial results for the last quarter of 2024, the year as a whole, and its guidance for 2025.
Today's issue
Refine Search
Biotechnology
Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million. 23 January 2025
Pharmaceutical
Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. 23 January 2025
Biotechnology
Flagship Pioneering, the USA-based bioplatform innovation company, has announced a new collaboration with UK-based healthcare groups. 23 January 2025
Pharmaceutical
Patients For Affordable Drugs, Public Citizen, Social Security Works and other campaigners are to gather in Washington, DC next week with the aim of delivering a message to pharma. 23 January 2025
Pharmaceutical
Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s Ascletis Pharma. 23 January 2025
Biotechnology
USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The Lancet Neurology. 23 January 2025
Pharmaceutical
An Expert View from Kevin Wild, head of pre-sales at software company Syniti. 23 January 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen, marketed as Spinraza, for spinal muscular atrophy (SMA). 23 January 2025
Biotechnology
A pair of Chinese biotech companies have filed to list on the Hong Kong Stock Exchange. 23 January 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical has received marketing authorization in China from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovative humanized monoclonal antibody (MAb) tagitanlimab (formerly KL-A167) used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). 23 January 2025
Pharmaceutical
Regulatory authorities, particularly the US Food and Drug Administration (FDA), have played a crucial role in accelerating and incentivizing the development of innovative treatments through review designations. 23 January 2025
Biotechnology
Xilio Therapeutics has reported initial results from its Phase II trial of vilastobart, an anti-CTLA-4 therapy, in combination with Roche's Tecentriq (atezolizumab). 23 January 2025
Biotechnology
USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. 23 January 2025
Biotechnology
US genetic meds company MeiraGTx Holdings yesterday revealed that the US Food and Drug Administration (FDA) has granted the company Rare Pediatric Disease (RPD) designation to its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). 23 January 2025
Pharmaceutical
Johnson & Johnson presented its financial results for the last quarter of 2024, the year as a whole, and its guidance for 2025. 22 January 2025
Pharmaceutical
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine glatiramer acetate (marketed under trade names including Copaxone, Glatopa), which is used to treat patients with multiple sclerosis (MS). 22 January 2025
Biotechnology
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of its shares on the Hong Kong Stock Exchange. 22 January 2025
Biotechnology
Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its cancer candidate. 22 January 2025
All news
Biotechnology
Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million. 23 January 2025
Pharmaceutical
Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. 23 January 2025
Biotechnology
Flagship Pioneering, the USA-based bioplatform innovation company, has announced a new collaboration with UK-based healthcare groups. 23 January 2025
Pharmaceutical
Patients For Affordable Drugs, Public Citizen, Social Security Works and other campaigners are to gather in Washington, DC next week with the aim of delivering a message to pharma. 23 January 2025
Pharmaceutical
Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s Ascletis Pharma. 23 January 2025
Biotechnology
USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The Lancet Neurology. 23 January 2025
Pharmaceutical
An Expert View from Kevin Wild, head of pre-sales at software company Syniti. 23 January 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen, marketed as Spinraza, for spinal muscular atrophy (SMA). 23 January 2025
Biotechnology
A pair of Chinese biotech companies have filed to list on the Hong Kong Stock Exchange. 23 January 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical has received marketing authorization in China from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovative humanized monoclonal antibody (MAb) tagitanlimab (formerly KL-A167) used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). 23 January 2025
Pharmaceutical
Regulatory authorities, particularly the US Food and Drug Administration (FDA), have played a crucial role in accelerating and incentivizing the development of innovative treatments through review designations. 23 January 2025
Biotechnology
Xilio Therapeutics has reported initial results from its Phase II trial of vilastobart, an anti-CTLA-4 therapy, in combination with Roche's Tecentriq (atezolizumab). 23 January 2025
Biotechnology
USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. 23 January 2025
Biotechnology
US genetic meds company MeiraGTx Holdings yesterday revealed that the US Food and Drug Administration (FDA) has granted the company Rare Pediatric Disease (RPD) designation to its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). 23 January 2025
Pharmaceutical
Johnson & Johnson presented its financial results for the last quarter of 2024, the year as a whole, and its guidance for 2025. 22 January 2025
Pharmaceutical
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine glatiramer acetate (marketed under trade names including Copaxone, Glatopa), which is used to treat patients with multiple sclerosis (MS). 22 January 2025
Biotechnology
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of its shares on the Hong Kong Stock Exchange. 22 January 2025
Biotechnology
Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its cancer candidate. 22 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze